Ayman O S El-Kadi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6554895/publications.pdf

Version: 2024-02-01

113 papers	3,890 citations	156536 32 h-index	190340 53 g-index
115 all docs	115 docs citations	115 times ranked	4621 citing authors

#	Article	IF	Citations
1	Identifying simultaneous matrix metalloproteinases/soluble epoxide hydrolase inhibitors. Molecular and Cellular Biochemistry, 2022, 477, 877-884.	1.4	0
2	The multifaceted role of cytochrome P450-Derived arachidonic acid metabolites in diabetes and diabetic cardiomyopathy. Drug Metabolism Reviews, 2022, 54, 141-160.	1.5	11
3	Ameliorative Role of Fluconazole Against Abdominal Aortic Constrictionâ€"Induced Cardiac Hypertrophy in Rats. Journal of Cardiovascular Pharmacology, 2022, 79, 833-845.	0.8	5
4	Targeting arachidonic acidâ€"related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles. Emergent Materials, 2021, 4, 265-277.	3.2	20
5	Novel Synthetic Analogues of 19(S/R)-Hydroxyeicosatetraenoic Acid Exhibit Noncompetitive Inhibitory Effect on the Activity of Cytochrome P450 1A1 and 1B1. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 613-624.	0.6	5
6	Arsenic: Various species with different effects on cytochrome P450 regulation in humans. EXCLI Journal, 2021, 20, 1184-1242.	0.5	0
7	Sex differences in eicosanoid formation and metabolism: A possible mediator of sex discrepancies in cardiovascular diseases. , 2021, , 108046.		14
8	Dronedarone: the effect of diet-induced obesity on its metabolism and experimental hyperlipidemia on its metabolism and tissue distribution in the rat. Canadian Journal of Physiology and Pharmacology, 2020, 98, 177-181.	0.7	1
9	Cytochrome P450-derived eicosanoids and inflammation in liver diseases. Prostaglandins and Other Lipid Mediators, 2020, 147, 106400.	1.0	26
10	Dietary-Induced Obesity, Hepatic Cytochrome P450, and Lidocaine Metabolism: Comparative Effects of High-Fat Diets in Mice and Rats and Reversibility of Effects With Normalization of Diet. Journal of Pharmaceutical Sciences, 2020, 109, 1199-1210.	1.6	8
11	Breast cancer diagnosis is associated with relative left ventricular hypertrophy and elevated endothelin-1 signaling. BMC Cancer, 2020, 20, 751.	1.1	10
12	Resveratrol attenuates angiotensin II-induced cellular hypertrophy through the inhibition of CYP1B1 and the cardiotoxic mid-chain HETE metabolites. Molecular and Cellular Biochemistry, 2020, 471, 165-176.	1.4	13
13	Phytocannabinoid drug-drug interactions and their clinical implications. , 2020, 215, 107621.		15
14	Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms. Medical Hypotheses, 2020, 144, 110033.	0.8	38
15	Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure. Circulation: Heart Failure, 2020, 13, e006277.	1.6	153
16	Fluconazole Represses Cytochrome P450 1B1 and Its Associated Arachidonic Acid Metabolites in the Heart and Protects Against Angiotensin II-Induced Cardiac Hypertrophy. Journal of Pharmaceutical Sciences, 2020, 109, 2321-2335.	1.6	11
17	Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy. Journal of Cardiovascular Pharmacology, 2019, 74, 235-245.	0.8	11
18	Subterminal hydroxyeicosatetraenoic acids: Crucial lipid mediators in normal physiology and disease states. Chemico-Biological Interactions, 2019, 299, 140-150.	1.7	35

#	Article	IF	Citations
19	Identification of 19-(S/R)Hydroxyeicosatetraenoic Acid as the First Endogenous Noncompetitive Inhibitor of Cytochrome P450 1B1 with Enantioselective Activity. Drug Metabolism and Disposition, 2019, 47, 67-70.	1.7	11
20	Fluconazole Inhibits Cytochrome P450 1B1 and its Associated Arachidonic Acid Metabolites in the Heart and Protects against Angiotensin IIâ€induced Cardiac Hypertrophy. FASEB Journal, 2019, 33, 817.10.	0.2	0
21	Resveratrol Protects Against Angiotensin IIâ€Induced Cellular Hypertrophy through Inhibition of CYP1B1/Midâ€Chain Hydroxyeicosatetraenoic Acid Mechanism. FASEB Journal, 2019, 33, 817.3.	0.2	0
22	2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy. Scientific Reports, 2018, 8, 2780.	1.6	30
23	Dimethylarsinic acid modulates the aryl hydrocarbon receptor-regulated genes in C57BL/6 mice: in vivo study. Xenobiotica, 2018, 48, 124-134.	0.5	5
24	The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity. Cardiovascular Toxicology, 2018, 18, 268-283.	1.1	6
25	DHA and 19,20-EDP induce lysosomal-proteolytic-dependent cytotoxicity through de novo ceramide production in H9c2 cells with a glycolytic profile. Cell Death Discovery, 2018, 4, 29.	2.0	9
26	Resveratrol improves cardiac function and exercise performance in MI-induced heart failure through the inhibition of cardiotoxic HETE metabolites. Journal of Molecular and Cellular Cardiology, 2018, 125, 162-173.	0.9	33
27	DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways. Pharmaceutics, 2018, 10, 144.	2.0	13
28	S-Enantiomer of 19-Hydroxyeicosatetraenoic Acid Preferentially Protects Against Angiotensin II-Induced Cardiac Hypertrophy. Drug Metabolism and Disposition, 2018, 46, 1157-1168.	1.7	28
29	Mitochondrial dysfunction induced by ceramide accumulation is involved in the cytotoxicity of 19, 20-epoxydocosapentaenoic acid in H9c2 cells. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-3-21.	0.0	0
30	Down-regulation of cytochrome P450 1A1 by monomethylarsonous acid in human HepG2 cells. Toxicology Letters, 2017, 270, 34-50.	0.4	14
31	The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol. Molecular and Cellular Biochemistry, 2017, 429, 151-165.	1.4	28
32	The Obesogenic Potency of Various High-Caloric Diet Compositions in Male Rats, and Their Effects on Expression of Liver and Kidney Proteins Involved in Drug Elimination. Journal of Pharmaceutical Sciences, 2017, 106, 1650-1658.	1.6	8
33	Mechanistically elucidating the in vitro safety and efficacy of a novel doxorubicin derivative. Drug Delivery and Translational Research, 2017, 7, 582-597.	3.0	11
34	Inhibition of Mid-chain HETEs Protects Against Angiotensin IIâ€“induced Cardiac Hypertrophy. Journal of Cardiovascular Pharmacology, 2017, 70, 16-24.	0.8	18
35	Differential eNOS-signalling by platelet subpopulations regulates adhesion and aggregation. Cardiovascular Research, 2017, 113, 1719-1731.	1.8	47
36	Development of a college-level assessment framework in line with international accreditation standards: A Middle Eastern perspective. Currents in Pharmacy Teaching and Learning, 2017, 9, 115-120.	0.4	10

#	Article	IF	Citations
37	Microsomal cytochrome P450 as a target for drug discovery and repurposing. Drug Metabolism Reviews, 2017, 49, 1-17.	1.5	22
38	Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain: An Emerging Therapeutic Target. Pharmaceutics, 2017, 9, 9.	2.0	45
39	The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy. Archives of Toxicology, 2016, 90, 119-136.	1.9	39
40	Ketoconazole Stereoisomers Differentially Induce Cytochrome P450 1A1 Between Human Hepatoma HepG2 and Mouse Hepatoma Hepa1c1c7 Cells. Journal of Pharmaceutical Sciences, 2016, 105, 1318-1326.	1.6	1
41	5-, 12- and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK- and NF-ÎºB-dependent mechanism. Archives of Toxicology, 2016, 90, 359-373.	1.9	29
42	CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism. Pharmacological Research, 2016, 105, 28-43.	3.1	37
43	Repurposing Resveratrol and Fluconazole To Modulate Human Cytochrome P450-Mediated Arachidonic Acid Metabolism. Molecular Pharmaceutics, 2016, 13, 1278-1288.	2.3	28
44	Modulation of aryl hydrocarbon receptor regulated genes by acute administration of trimethylarsine oxide in the lung, kidney and heart of C57BL/6 mice. Xenobiotica, 2015, 45, 930-943.	0.5	11
45	Metformin inhibits 7,12-dimethylbenz[a]anthracene-induced breast carcinogenesis and adduct formation in human breast cells by inhibiting the cytochrome P4501A1/aryl hydrocarbon receptor signaling pathway. Toxicology and Applied Pharmacology, 2015, 284, 217-226.	1.3	29
46	Modulation of aryl hydrocarbon receptor-regulated enzymes by trimethylarsine oxide in C57BL/6 mice: In vivo and in vitro studies. Toxicology Letters, 2015, 238, 17-31.	0.4	10
47	Early Changes in Cytochrome P450s and Their Associated Arachidonic Acid Metabolites Play a Crucial Role in the Initiation of Cardiac Hypertrophy Induced by Isoproterenol. Drug Metabolism and Disposition, 2015, 43, 1254-1266.	1.7	24
48	Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: Roles of the NF-ÎºB and MAPK signaling pathways. Free Radical Biology and Medicine, 2015, 82, 1-12.	1.3	31
49	Development of cellular hypertrophy by 8-hydroxyeicosatetraenoic acid in the human ventricular cardiomyocyte, RL-14 cell line, is implicated by MAPK and NF-ÎºB. Cell Biology and Toxicology, 2015, 31, 241-259.	2.4	27
50	19-Hydroxyeicosatetraenoic acid and isoniazid protect against angiotensin II-induced cardiac hypertrophy. Toxicology and Applied Pharmacology, 2015, 289, 550-559.	1.3	27
51	Human fetal ventricular cardiomyocyte, RL-14 cell line, is a promising model to study drug metabolizing enzymes and their associated arachidonic acid metabolites. Journal of Pharmacological and Toxicological Methods, 2015, 71, 33-41.	0.3	27
52	Design and synthesis of resveratrolâ€“salicylate hybrid derivatives as CYP1A1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 884-895.	2.5	13
53	Buthionine Sulfoximine, an Inhibitor of Glutathione Biosynthesis, Induces Expression of Soluble Epoxide Hydrolase and Cellular Hypertrophy Markers in a Rat Cardiomyoblast Cell Line: Roles of The NFâ€ºB And MAPK Signalling Pathways. FASEB Journal, 2015, 29, 1025.6.	0.2	0
54	Acute arsenic treatment alters arachidonic acid and its associated metabolite levels in the brain of C57Bl/6 mice. Canadian Journal of Physiology and Pharmacology, 2014, 92, 693-702.	0.7	21

#	Article	IF	Citations
55	The role of epoxide hydrolases in health and disease. Archives of Toxicology, 2014, 88, 2013-2032.	1.9	53
56	Fenofibrate Modulates Cytochrome P450 and Arachidonic Acid Metabolism in the Heart and Protects Against Isoproterenol-induced Cardiac Hypertrophy. Journal of Cardiovascular Pharmacology, 2014, 63, 167-177.	0.8	21
57	Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57Bl/6 mouse heart. Toxicology Letters, 2014, 226, 53-62.	0.4	22
58	Methylated pentavalent arsenic metabolites are bifunctional inducers, as they induce cytochrome P450 1A1 and NAD(P)H:quinone oxidoreductase through AhR- and Nrf2-dependent mechanisms. Free Radical Biology and Medicine, 2014, 67, 171-187.	1.3	30
59	Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy. Biochemical Pharmacology, 2014, 87, 456-466.	2.0	44
60	Characterization of Arachidonic Acid Metabolism by Rat Cytochrome P450 Enzymes: The Involvement of CYP1As. Drug Metabolism and Disposition, 2014, 42, 1498-1507.	1.7	54
61	Modulation of aryl hydrocarbon receptorâ€regulated genes by acute administration of ammonium metavanadate in kidney, lung and heart of C57BL/6 mice. Journal of Applied Toxicology, 2013, 33, 1230-1240.	1.4	1
62	Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice. Archives of Toxicology, 2013, 87, 1531-1543.	1.9	7
63	Mercury modulates the cytochrome P450 1a1, 1a2 and 1b1 in C57BL/6J mice: in vivo and in vitro studies. Toxicology and Applied Pharmacology, 2013, 266, 419-429.	1.3	9
64	Differential modulation of cytochrome P450 1a1 by arsenite in vivo and in vitro in C57BL/6 mice. Free Radical Biology and Medicine, 2013, 58, 52-63.	1.3	12
65	Murine atrial HL-1 cell line is a reliable model to study drug metabolizing enzymes in the heart. Vascular Pharmacology, 2013, 58, 326-333.	1.0	18
66	Determination of the Dominant Arachidonic Acid Cytochrome P450 Monooxygenases in Rat Heart, Lung, Kidney, and Liver: Protein Expression and Metabolite Kinetics. AAPS Journal, 2013, 15, 112-122.	2.2	39
67	Posttranslational mechanisms modulating the expression of the cytochrome P450 1A1 gene by methylmercury in HepG2 cells: A role of heme oxygenase-1. Toxicology Letters, 2013, 219, 239-247.	0.4	9
68	Cytochrome P450 epoxygenase metabolite, 14,15-EET, protects against isoproterenol-induced cellular hypertrophy in H9c2 rat cell line. Vascular Pharmacology, 2013, 58, 363-373.	1.0	32
69	Acute arsenic treatment alters cytochrome P450 expression and arachidonic acid metabolism in lung, liver and kidney of C57Bl/6 mice. Xenobiotica, 2013, 43, 719-729.	0.5	16
70	Role of cytochrome P450â€“mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy. Drug Metabolism Reviews, 2013, 45, 173-195.	1.5	41
71	Soluble epoxide hydrolase inhibitor, <scp>TUPS</scp>, protects against isoprenalineâ€induced cardiac hypertrophy. British Journal of Pharmacology, 2013, 168, 1794-1807.	2.7	44
72	20-Hydroxyeicosatetraenoic Acid is a Potential Therapeutic Target in Cardiovascular Diseases. Current Drug Metabolism, 2013, 14, 706-719.	0.7	31

#	Article	IF	Citations
73	Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57Bl/6 mouse heart. Xenobiotica, 2012, 42, 1235-1247.	0.5	26
74	Chronic Doxorubicin Cardiotoxicity Modulates Cardiac Cytochrome P450-Mediated Arachidonic Acid Metabolism in Rats. Drug Metabolism and Disposition, 2012, 40, 2126-2135.	1.7	40
75	Inhibition of Heme Oxygenase-1 Partially Reverses the Arsenite-Mediated Decrease of CYP1A1, CYP1A2, CYP3A23, and CYP3A2 Catalytic Activity in Isolated Rat Hepatocytes. Drug Metabolism and Disposition, 2012, 40, 504-514.	1.7	19
76	Camel Milk Triggers Apoptotic Signaling Pathways in Human Hepatoma HepG2 and Breast Cancer MCF7 Cell Lines through Transcriptional Mechanism. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-9.	3.0	57
77	Effect of mercury on aryl hydrocarbon receptor-regulated genes in the extrahepatic tissues of C57BL/6 mice. Food and Chemical Toxicology, 2012, 50, 2325-2334.	1.8	10
78	Differential modulation of aryl hydrocarbon receptor regulated enzymes by arsenite in the kidney, lung, and heart of C57BL/6 mice. Archives of Toxicology, 2012, 86, 897-910.	1.9	31
79	Acute Doxorubicin Toxicity Differentially Alters Cytochrome P450 Expression and Arachidonic Acid Metabolism in Rat Kidney and Liver. Drug Metabolism and Disposition, 2011, 39, 1440-1450.	1.7	71
80	The effect of Nrf2 knockout on the constitutive expression of drug metabolizing enzymes and transporters in C57Bl/6 mice livers. Toxicology in Vitro, 2011, 25, 785-795.	1.1	51
81	Inhibition of Soluble Epoxide Hydrolase Confers Cardioprotection and Prevents Cardiac Cytochrome P450 Induction by Benzo(a)pyrene. Journal of Cardiovascular Pharmacology, 2011, 57, 273-281.	0.8	28
82	Transcriptional modulation of the NAD(P)H:quinone oxidoreductase 1 by mercury in human hepatoma HepG2 cells. Free Radical Biology and Medicine, 2011, 51, 1675-1685.	1.3	16
83	Transcriptional and posttranscriptional regulation of CYP1A1 by vanadium in human hepatoma HepG2 cells. Cell Biology and Toxicology, 2010, 26, 421-434.	2.4	15
84	Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. , 2010, 125, 446-463.		154
85	Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicology and Applied Pharmacology, 2010, 242, 38-46.	1.3	95
86	Arsenite down-regulates cytochrome P450 1A1 at the transcriptional and posttranslational levels in human HepG2 cells. Free Radical Biology and Medicine, 2010, 48, 1399-1409.	1.3	25
87	Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacological Research, 2010, 61, 410-418.	3.1	46
88	The effect of Î²-naphthoflavone on the metabolism of amiodarone by hepatic and extra-hepatic microsomes. Toxicology Letters, 2010, 195, 147-154.	0.4	21
89	2,3,7,8-Tetrachlorodibenzo-p-dioxin and Î²-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism. Toxicology in Vitro, 2010, 24, 863-871.	1.1	31
90	Modulation of NAD(P)H:quinone oxidoreductase by vanadium in human hepatoma HepG2 cells. Toxicology in Vitro, 2010, 24, 1554-1561.	1.1	16

#	Article	IF	Citations
91	Mercury modulates the CYP1A1 at transcriptional and posttranslational levels in human hepatoma HepG2 cells. Toxicology Letters, 2010, 199, 225-233.	0.4	25
92	Role of NF-κB in the Regulation of Cytochrome P450 Enzymes. Current Drug Metabolism, 2009, 10, 164-178.	0.7	152
93	Down-regulation of the detoxifying enzyme NAD(P)H:quinone oxidoreductase 1 by vanadium in Hepa 1c1c7 cells. Toxicology and Applied Pharmacology, 2009, 236, 261-269.	1.3	17
94	3â€Methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. British Journal of Pharmacology, 2009, 158, 1808-1819.	2.7	59
95	Sulforaphane induces CYP1A1 mRNA, protein, and catalytic activity levels via an AhR-dependent pathway in murine hepatoma Hepa 1c1c7 and human HepG2 cells. Cancer Letters, 2009, 275, 93-101.	3.2	51
96	MG-132 inhibits the TCDD-mediated induction of Cyp1a1 at the catalytic activity but not the mRNA or protein levels in Hepa 1c1c7 cells. Toxicology Letters, 2008, 182, 121-126.	0.4	11
97	Modulation of Cardiac and Hepatic Cytochrome P450 Enzymes During Heart Failure. Current Drug Metabolism, 2008, 9, 122-128.	0.7	68
98	Modulation of Cytochrome P450 Gene Expression and Arachidonic Acid Metabolism during Isoproterenol-Induced Cardiac Hypertrophy in Rats. Drug Metabolism and Disposition, 2008, 36, 2277-2286.	1.7	94
99	Down-Regulation of the Carcinogen-Metabolizing Enzyme Cytochrome P450 1a1 by Vanadium. Drug Metabolism and Disposition, 2008, 36, 1819-1827.	1.7	25
100	Induction of cytochrome P450 1a1 by the food flavoring agent, maltol. Toxicology in Vitro, 2007, 21, 685-690.	1.1	30
101	Constitutive expression and inducibility of CYP1A1 in the H9c2 rat cardiomyoblast cells. Toxicology in Vitro, 2007, 21, 1686-1691.	1.1	10
102	Induction of Cytochrome P450 1A1 by Ketoconazole and Itraconazole but not Fluconazole in Murine and Human Hepatoma Cell Lines. Toxicological Sciences, 2007, 97, 32-43.	1.4	47
103	Transcriptional activation and posttranscriptional modification of Cyp1a1 by arsenite, cadmium, and chromium. Toxicology Letters, 2007, 172, 106-119.	0.4	60
104	H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. Journal of Pharmacological and Toxicological Methods, 2007, 56, 317-322.	0.3	91
105	The Role of Aryl Hydrocarbon Receptor in the Pathogenesis of Cardiovascular Diseases. Drug Metabolism Reviews, 2006, 38, 411-450.	1.5	157
106	Cytochrome P450 enzymes: Central players in cardiovascular health and disease. , 2006, 112, 564-587.		151
107	Regulatory Mechanisms Modulating the Expression of Cytochrome P450 1A1 Gene by Heavy Metals. Toxicological Sciences, 2005, 88, 39-51.	1.4	82
108	tert-BUTYLHYDROQUINONE IS A NOVEL ARYL HYDROCARBON RECEPTOR LIGAND. Drug Metabolism and Disposition, 2005, 33, 365-372.	1.7	77

#	Article	IF	Citations
109	Differential effects of mercury, lead and copper on the constitutive and inducible expression of aryl hydrocarbon receptor (AHR)-regulated genes in cultured hepatoma Hepa 1c1c7 cells. Toxicology, 2004, 201, 153-172.	2.0	92
110	Modulation of aryl hydrocarbon receptor-regulated gene expression by arsenite, cadmium, and chromium. Toxicology, 2004, 202, 249-269.	2.0	81
111	Benzo[a]Pyrene, 3-Methylcholanthrene and ÃŸ-Naphthoflavone Induce Oxidative Stress in Hepatoma Hepa 1c1c7 Cells by an AHR-dependent Pathway. Free Radical Research, 2004, 38, 1191-1200.	1.5	55
112	The Effect of Liver Cirrhosis on the Regulation and Expression of Drug Metabolizing Enzymes. Current Drug Metabolism, 2004, 5, 157-167.	0.7	127
113	Down-regulation of the hepatic cytochrome P450 by an acute inflammatory reaction: implication of mediators in human and animal serum and in the liver. British Journal of Pharmacology, 1997, 121, 1164-1170.	2.7	25